NZ552481A - Compositions and methods for treating eye disorders and conditions - Google Patents

Compositions and methods for treating eye disorders and conditions

Info

Publication number
NZ552481A
NZ552481A NZ552481A NZ55248105A NZ552481A NZ 552481 A NZ552481 A NZ 552481A NZ 552481 A NZ552481 A NZ 552481A NZ 55248105 A NZ55248105 A NZ 55248105A NZ 552481 A NZ552481 A NZ 552481A
Authority
NZ
New Zealand
Prior art keywords
omega
composition
fatty acid
acid
weight
Prior art date
Application number
NZ552481A
Other languages
English (en)
Inventor
Reza Dana
Debra Schaumberg
Frank Molock
Lenora Copper
Shiv Mahadevan
Kathy Osborn Lorenz
Saadia Rashid
Original Assignee
Schepens Eye Res
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ552481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schepens Eye Res, Johnson & Johnson Vision Care filed Critical Schepens Eye Res
Publication of NZ552481A publication Critical patent/NZ552481A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ552481A 2004-07-01 2005-06-30 Compositions and methods for treating eye disorders and conditions NZ552481A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58451404P 2004-07-01 2004-07-01
PCT/US2005/023113 WO2006007510A1 (en) 2004-07-01 2005-06-30 Compositions and methods for treating eye disorders and conditions

Publications (1)

Publication Number Publication Date
NZ552481A true NZ552481A (en) 2008-12-24

Family

ID=35784207

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552481A NZ552481A (en) 2004-07-01 2005-06-30 Compositions and methods for treating eye disorders and conditions

Country Status (15)

Country Link
US (2) US20060009522A1 (https=)
EP (1) EP1781278B2 (https=)
JP (1) JP2008505177A (https=)
KR (1) KR20070040381A (https=)
CN (1) CN101043884A (https=)
AU (1) AU2005262392A1 (https=)
BR (1) BRPI0512864B8 (https=)
CA (1) CA2572344A1 (https=)
IL (1) IL180342A0 (https=)
MX (1) MX2007000208A (https=)
NO (1) NO20070561L (https=)
NZ (1) NZ552481A (https=)
RU (1) RU2007103835A (https=)
WO (1) WO2006007510A1 (https=)
ZA (1) ZA200700918B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
AU2005296212A1 (en) * 2004-10-19 2006-04-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Topical treatment with NGF and DHA in damaged corneas
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8496976B2 (en) 2009-06-05 2013-07-30 Allergan, Inc. Artificial tears and therapeutic uses
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DE102010050570A1 (de) 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN105997973A (zh) * 2010-11-19 2016-10-12 日本水产株式会社 用于角膜上皮病变和/或结膜上皮病变的治疗剂或预防剂
WO2012145119A2 (en) * 2011-04-17 2012-10-26 Michael Gurin Low inflammatory blended oils
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US20160310456A1 (en) * 2013-03-12 2016-10-27 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
CN103998034A (zh) * 2011-09-12 2014-08-20 塔索斯·乔治欧 ω脂肪酸用于治疗疾病的用途
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
EP2664330A1 (de) 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
JP2015526515A (ja) * 2012-08-31 2015-09-10 ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ オメガ３脂肪酸を有する眼用組成物
US8673325B1 (en) * 2012-09-06 2014-03-18 Dignity Sciences Limited Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10702416B2 (en) 2013-02-26 2020-07-07 Belkin Laser Ltd. System for glaucoma treatment
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
WO2015042442A1 (en) * 2013-09-19 2015-03-26 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
ES2784240T3 (es) 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
CN106963728A (zh) * 2016-01-13 2017-07-21 汤欣 一种二十二碳六烯酸结膜下注射液的制备方法及其应用
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
ES2982698T3 (es) * 2020-01-23 2024-10-17 Visufarma S P A Composición oftálmica para el tratamiento de la enfermedad del ojo seco
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR20230158076A (ko) * 2021-03-18 2023-11-17 제니비젼 인크. 눈 질환을 치료하기 위한 방법 및 조성물

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437014A (en) * 1890-09-23 Swing
US3572913A (en) * 1969-02-03 1971-03-30 Boylston Res Ass Comprehensive support for ophthalmic examination apparatus and instruments
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4180308A (en) * 1972-10-02 1979-12-25 Syntex (Usa) Inc. Contact lens
US4401372A (en) * 1972-10-02 1983-08-30 Syntex (U.S.A.) Inc. Contact lens
DE2309440A1 (de) * 1973-02-26 1974-09-05 Katz Verfahren zum isolieren von lysozym
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4313355A (en) * 1978-02-06 1982-02-02 Syntex (U.S.A.) Inc. Method and apparatus for manufacturing plastic lenses
US4202226A (en) * 1978-02-06 1980-05-13 SyntexLaboratories, Inc. Method and apparatus for manufacturing plastic lenses
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4379864A (en) * 1979-02-09 1983-04-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4338419A (en) * 1979-02-09 1982-07-06 Syntex (U.S.A.) Inc. Process for treatment of hydrogel lens with thiols
US4543371A (en) * 1981-03-05 1985-09-24 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US5145686A (en) * 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
ATE24266T1 (de) 1982-04-16 1987-01-15 Nestle Sa Lipidhaltige zusammensetzung fuer die orale, enterale oder parenterale ernaehrung.
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
US4678698A (en) * 1983-04-12 1987-07-07 Minnesota Mining And Manufacturing Company Contact lens cleaning article
US4622258A (en) * 1983-04-12 1986-11-11 Minnesota Mining And Manufacturing Company Contact lens cleaning article
US4533399A (en) * 1983-04-12 1985-08-06 Minnesota Mining And Manufacturing Company Contact lens cleaning method
JPS6158539A (ja) * 1984-08-29 1986-03-25 Nisshin Oil Mills Ltd:The スナツク様菓子の製造法
US4613380A (en) * 1985-04-01 1986-09-23 Dow Corning Corporation Method for removing lipid deposits from contact lenses
US5484432A (en) * 1985-09-27 1996-01-16 Laser Biotech, Inc. Collagen treatment apparatus
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5240702A (en) * 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
CA1263270A (en) * 1987-08-19 1989-11-28 Bruce J. Holub Animal feed supplement
US5111221A (en) * 1988-05-13 1992-05-05 United States Of America As Represented By The Secretary Of The Navy Receptor-based sensor
US5225374A (en) * 1988-05-13 1993-07-06 The United States Of America As Represented By The Secretary Of The Navy Method of fabricating a receptor-based sensor
US4923700A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Artificial tear suspension
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5278142A (en) * 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5206298A (en) * 1989-12-19 1993-04-27 Tomei Sangyo Kabushiki Kaisha Graft copolymer, solution containing the graft copolymer for treating contact lens, and method of treating contact lens with the solution and making hydrophilic lens surface
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) * 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
US5167323A (en) * 1990-08-09 1992-12-01 Tomei Sangyo Co., Ltd. Lens treating device for treating contact lens
US5181604A (en) * 1990-09-14 1993-01-26 Tomei Sangyo Co., Ltd. Contact lens holder and treating device
US5203337A (en) * 1991-05-08 1993-04-20 Brigham And Women's Hospital, Inc. Coronary artery imaging system
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
JPH06122627A (ja) * 1992-10-13 1994-05-06 Sagami Chem Res Center 抗アレルギー点眼液
US5378488A (en) * 1993-06-10 1995-01-03 Abbott Laboratories Aseptic processing of infant formula
AU1520095A (en) * 1993-12-29 1995-07-17 Bausch & Lomb Incorporated Carbohydrate composition and method for cleaning and disinfecting contact lenses
US6060644A (en) * 1994-03-24 2000-05-09 Iowa State University Research Foundation, Inc. Isolation and use of cuticular lipid genes
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6113894A (en) * 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
BR9711019A (pt) * 1996-08-02 1999-08-17 Plum Kemi Prod EmulsÆo de Äleo-em- gua para uso em pela humana para limpeza preserva-Æo ou aperfei-oamento da condi-Æo da pele
EA002520B1 (ru) * 1996-09-20 2002-06-27 Атеродженикс, Инк. Выделенное антитело и его фрагмент, способы и набор для оценки уровня перекисного окисления липидов в биологическом образце и способ диагностики заболеваний, обусловленных перекисным окислением липидов
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
JPH10218760A (ja) 1997-02-04 1998-08-18 Nobel Igaku Kenkyusho:Kk ドライアイ治療用の微量油添加目薬
AP9901670A0 (en) * 1997-03-03 1999-12-31 Adcock Ingram Ltd A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease.
US6107365A (en) * 1997-09-03 2000-08-22 The Regents Of The University Of California Biomimetic hydrogel materials
US6475784B1 (en) * 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
CN1175904C (zh) 1998-05-15 2004-11-17 若素制药株式会社 抗炎滴眼剂
US6346594B1 (en) * 1998-09-21 2002-02-12 Menicon Co., Ltd. Ocular lens material and process for producing same
JP2002538124A (ja) * 1999-03-01 2002-11-12 ヴィスタ サイエンティフィック エルエルシー ムチンを含む眼科用調合物
US6429194B1 (en) * 1999-03-01 2002-08-06 Vista Scientific Llc Mucin containing ophthalmic preparation
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
AUPQ228199A0 (en) 1999-08-18 1999-09-09 Sly, Anthony William Ophthalmic fluid
AU7638300A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates and microemulsions
US6286955B1 (en) * 1999-12-15 2001-09-11 Tetsuya Sakai Biocompatible lens, and method of producing the same
US6344047B1 (en) * 2000-02-02 2002-02-05 Eagle Vision Instrument for inserting a punctum plug and method for manufacturing the instrument
US6533415B2 (en) * 2000-03-21 2003-03-18 Menicon Co., Ltd. Ocular lens material having hydrophilic surface and process for preparing the same
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
WO2002009803A1 (en) * 2000-08-01 2002-02-07 Ocular Research Of Boston, Inc. Visual discomfort relief
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6667047B2 (en) * 2001-07-27 2003-12-23 International Flute Technologies Ltd Ultra-stable composition comprising moringa oil and its derivatives and uses thereof
WO2003018049A2 (en) * 2001-08-23 2003-03-06 Westgate Biological Limited Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
US20040076691A1 (en) * 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
JP2005529945A (ja) * 2002-06-17 2005-10-06 リソルヴィックス ファーマシューティカルズ オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
WO2004006801A2 (en) * 2002-07-17 2004-01-22 Biosyntrx, Inc. Treatment for dry eye syndrome
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP2005008570A (ja) * 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface

Also Published As

Publication number Publication date
NO20070561L (no) 2007-03-30
EP1781278A1 (en) 2007-05-09
BRPI0512864A (pt) 2008-04-08
RU2007103835A (ru) 2008-08-10
MX2007000208A (es) 2007-08-07
AU2005262392A1 (en) 2006-01-19
EP1781278A4 (en) 2009-09-02
CN101043884A (zh) 2007-09-26
US20080153909A1 (en) 2008-06-26
EP1781278B2 (en) 2019-10-16
IL180342A0 (en) 2007-07-04
BRPI0512864B8 (pt) 2021-05-25
WO2006007510A1 (en) 2006-01-19
KR20070040381A (ko) 2007-04-16
US20060009522A1 (en) 2006-01-12
ZA200700918B (en) 2008-10-29
EP1781278B1 (en) 2016-08-10
BRPI0512864B1 (pt) 2021-04-27
JP2008505177A (ja) 2008-02-21
CA2572344A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
EP1781278B1 (en) Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) Compositions and methods for treating eye disorders and conditions
KR101677308B1 (ko) 오메가-3 및 오메가-6 다가 불포화 지방산계 안과용 조성물
CN103533962B (zh) 一种眼用组合物
JP6675361B2 (ja) 眼の炎症状態を治療するためのエステル
JP2022506684A (ja) 人工涙液
EP3280395B1 (en) Ophthalmic compositions based on polyunsaturated fatty acids and triacylglycerols
WO2023055321A1 (en) Anti-inflammatory microemulsion eye formulations derived from nigella sativa oil
HK1166714B (en) Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids
CN104771354B (zh) 用于眼用的基于非极性和极性脂质的药物制剂
HK40066479A (zh) 人工泪液

Legal Events

Date Code Title Description
PSEA Patent sealed